Compare XLO & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XLO | XTNT |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.9M | 61.7M |
| IPO Year | 2021 | 2009 |
| Metric | XLO | XTNT |
|---|---|---|
| Price | $9.17 | $0.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $28.00 | $1.00 |
| AVG Volume (30 Days) | 23.3K | ★ 127.5K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.00 |
| EPS | N/A | ★ N/A |
| Revenue | $43,766,000.00 | ★ $53,337,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $168.77 | $9.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 589.88 | N/A |
| 52 Week Low | $0.46 | $0.27 |
| 52 Week High | $9.89 | $0.95 |
| Indicator | XLO | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 21.45 |
| Support Level | $7.47 | N/A |
| Resistance Level | $9.22 | $0.47 |
| Average True Range (ATR) | 0.38 | 0.03 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 54.04 | 20.02 |
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.